Timed and targeted therapy for acute kidney injury: a glimpse of the future.
Whether and when to intervene and with which therapeutic agent are key questions physicians face daily in managing patients. Biomarkers are emerging to define the course of acute kidney injury and offer an opportunity to provide targeted interventions. The EARLYARF study by Endre et al. provides a glimpse of the challenges and opportunities that lie ahead.
Mehta
Ravindra L
RL
Division of Nephrology and Hypertension, Department of Medicine, University of California, San Diego, California, USA. rmehta@ucsd.edu
D000208:Acute Disease; D000469:Alkaline Phosphatase / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007362:Intensive Care Units; D007674:Kidney Diseases / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D018579:Patient Selection; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014218:Triage; D005723:gamma-Glutamyltransferase / Q000652:urine
D015415:Biomarkers; D006397:Hematinics; D004921:Erythropoietin; D003404:Creatinine; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase